Komori
General Meetings of Shareholders4538Fuso Pharmaceutical Industries,Ltd.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials

The 103rd Annual General Meeting of Shareholders will be held on 24 June 2026, with two proposals submitted for consideration: a dividend and the payment of retirement bonuses to retiring directors. Shareholders may exercise their voting rights in writing, via the internet or by other means.

Worth reading
42Recurring
Scored from 3 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (103rd)
2026
Jun 24
Date and time23 days from this disclosure to the meeting
Matters for resolution2 items
  1. Disposition of surplus

  2. Payment of retirement bonuses to retiring directors

Shareholder Proposal

Not disclosed

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (103rd)
Date and time10:00 a.m. on Wednesday, 24 June 2026
Matters for resolutionProposal No. 1: Disposition of surplus, Proposal 2: Payment of retirement bonuses to retiring directors
Shareholder ProposalNot disclosed
Items this document does not state (2)
Director nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The purpose is to hold the Annual General Meeting of Shareholders and obtain shareholder approval for the disposal of surplus and the payment of retirement bonuses to retiring directors. For Proposal 1, the company states that it has comprehensively considered its basic policy of prioritising shareholder returns and striving to maintain stable dividends, as well as its business performance, operating environment and the need to strengthen its financial position. Proposal 2 is intended to reward the retiring directors for their contributions during their tenure.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials | Fuso Pharmaceutical Industries,Ltd. (4538) timely disclosure | Komori